Oliver Luxxe Assets LLC Has $9.46 Million Stake in AbbVie Inc. $ABBV

Oliver Luxxe Assets LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 6.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,842 shares of the company’s stock after buying an additional 2,517 shares during the quarter. AbbVie comprises approximately 1.5% of Oliver Luxxe Assets LLC’s investment portfolio, making the stock its 12th biggest position. Oliver Luxxe Assets LLC’s holdings in AbbVie were worth $9,457,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Marshall & Sullivan Inc. WA bought a new stake in AbbVie during the second quarter worth about $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. bought a new position in AbbVie in the second quarter valued at approximately $36,000. Finally, Delos Wealth Advisors LLC acquired a new position in AbbVie during the second quarter valued at approximately $39,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV?243 safety data, progress on icalcaprant, and completed real?world studies for Rinvoq and upadacitinib), supporting longer?term revenue diversification away from Humira. ABBV?243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY?2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income?oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short?term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY?2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near?term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near?term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

AbbVie Stock Down 1.8%

Shares of NYSE:ABBV opened at $220.06 on Friday. The firm has a market cap of $388.93 billion, a P/E ratio of 166.71, a P/E/G ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The business has a fifty day simple moving average of $226.59 and a 200 day simple moving average of $215.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is presently 496.97%.

Analysts Set New Price Targets

Several research firms recently weighed in on ABBV. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. UBS Group assumed coverage on shares of AbbVie in a research report on Wednesday. They set a “neutral” rating and a $240.00 price objective for the company. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 price target (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.